A California federal judge has reportedly allowed litigation to proceed against Abbott Laboratories (NYSE:ABT) regarding its Glucerna shakes and nutritional powders. The lawsuit claims these products, ...
Novo Nordisk and Eli Lilly have generated billions of dollars in revenue selling weight loss drugs. Abbott Labs is launching a complementary product for those on the weight loss path. Abbott Labs is ...
Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Abbott Laboratories CEO Robert Ford adamantly defended the ...
Abbott Laboratories has underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s prospects.
Abbott Laboratories (NYSE:ABT) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February ...
StockStory.org on MSN
Abbott Laboratories (NYSE:ABT) Posts Q4 Sales In Line With Estimates
Healthcare product and device company Abbott Laboratories (NYSE:ABT) in Q4 CY2024, with sales up 7.2% year on year to $10.97 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results